Thrombotic microangiopathy and retroviral infections: A 13‐year experience

Eleven of fifty serum samples collected from patients with a diagnosis of thrombotic microangiopathy (TMA), from 1979 to 1991, tested positive for antlretroviral antibodies. Seven had human immunodeficiency virus (HIV) infection, and four had human iymphotrophic virus, type I (HTLV‐I) infection. All...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of hematology 1994-04, Vol.45 (4), p.304-309
Hauptverfasser: Ucar, Antonio, Fernandez, Hugo F., Byrnes, John J., Lian, Eric C‐Y, Harrington, William J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 309
container_issue 4
container_start_page 304
container_title American journal of hematology
container_volume 45
creator Ucar, Antonio
Fernandez, Hugo F.
Byrnes, John J.
Lian, Eric C‐Y
Harrington, William J.
description Eleven of fifty serum samples collected from patients with a diagnosis of thrombotic microangiopathy (TMA), from 1979 to 1991, tested positive for antlretroviral antibodies. Seven had human immunodeficiency virus (HIV) infection, and four had human iymphotrophic virus, type I (HTLV‐I) infection. All patients were treated with plasma exchange and for infusion, but only two of the HIV‐infected patlents obtained a complete response (CR) and one of them died after a few months. Combined results from the ilterature indicate that most patients with HIV infection survive less than one year from the initial diagnosis of TMA. In the setting of HIV infection, TMA Is a treatable condition, but survivai for most patients is less than 12 months. Three of the four HTLV‐I infected patients with TMA had a CR. These observations strongly suggest that both HIV and HTLV‐I infections are associated with TMA, but rigorous epidemiologic studies will be needed to determine the relative risk for each. Retrovirai Infections should be considered In patients with TMA, especially If the patient has associated risk factors and demographic characteristics. © 1994 Wiley‐Liss, Inc.
doi_str_mv 10.1002/ajh.2830450407
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_76488306</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>76488306</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4647-a50f0fe97238aa9b4030f78d95451721095349bd2bac923c5355a16aaa3f37e63</originalsourceid><addsrcrecordid>eNqFkLlOw0AQQFcIFEKgpUNygegSZi_bSxdFQECRaEJtjddrspGPsOsA6fgEvpEvwVGsQEc1I82b6xFyTmFEAdg1LhcjFnMQEgREB6RPQYXDOJTskPSBh7TNQR2TE--XAJSKGHqkFylQKmZ9MpsvXF2mdWN1UFrtaqxebL3CZrEJsMoCZxpXv1mHRWCr3OjG1pW_CcYB5d-fXxuDLjAfK-OsqbQ5JUc5Ft6cdXFAnu9u55PpcPZ0_zAZz4ZahCIaooQccqMixmNElQrgkEdxpqSQNGLtA5ILlWYsRa0Y15JLiTRERJ7zyIR8QK52c1eufl0b3ySl9doUBVamXvskCkXcKtmCox3YPua9M3mycrZEt0koJFt9Sasv-dXXNlx0k9dpabI93vlq65ddHb3GIndYaev3GFexVIy2mNph77Ywm3-WJuPH6Z8TfgBg44ii</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76488306</pqid></control><display><type>article</type><title>Thrombotic microangiopathy and retroviral infections: A 13‐year experience</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Ucar, Antonio ; Fernandez, Hugo F. ; Byrnes, John J. ; Lian, Eric C‐Y ; Harrington, William J.</creator><creatorcontrib>Ucar, Antonio ; Fernandez, Hugo F. ; Byrnes, John J. ; Lian, Eric C‐Y ; Harrington, William J.</creatorcontrib><description>Eleven of fifty serum samples collected from patients with a diagnosis of thrombotic microangiopathy (TMA), from 1979 to 1991, tested positive for antlretroviral antibodies. Seven had human immunodeficiency virus (HIV) infection, and four had human iymphotrophic virus, type I (HTLV‐I) infection. All patients were treated with plasma exchange and for infusion, but only two of the HIV‐infected patlents obtained a complete response (CR) and one of them died after a few months. Combined results from the ilterature indicate that most patients with HIV infection survive less than one year from the initial diagnosis of TMA. In the setting of HIV infection, TMA Is a treatable condition, but survivai for most patients is less than 12 months. Three of the four HTLV‐I infected patients with TMA had a CR. These observations strongly suggest that both HIV and HTLV‐I infections are associated with TMA, but rigorous epidemiologic studies will be needed to determine the relative risk for each. Retrovirai Infections should be considered In patients with TMA, especially If the patient has associated risk factors and demographic characteristics. © 1994 Wiley‐Liss, Inc.</description><identifier>ISSN: 0361-8609</identifier><identifier>EISSN: 1096-8652</identifier><identifier>DOI: 10.1002/ajh.2830450407</identifier><identifier>PMID: 7909982</identifier><identifier>CODEN: AJHEDD</identifier><language>eng</language><publisher>New York: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adult ; AIDS (acquired immunodeficiency syndrome) ; AIDS-Related Opportunistic Infections - blood ; AIDS-Related Opportunistic Infections - epidemiology ; AIDS/HIV ; Biological and medical sciences ; Deltaretrovirus Antibodies - analysis ; Deltaretrovirus Antibodies - immunology ; DNA, Viral - analysis ; DNA, Viral - genetics ; Female ; Hematologic and hematopoietic diseases ; Hemolytic-Uremic Syndrome - blood ; Hemolytic-Uremic Syndrome - complications ; Hemolytic-Uremic Syndrome - epidemiology ; HIV (human immunodeficiency virus) ; HIV - genetics ; HIV - immunology ; HIV Antibodies - analysis ; HIV Antibodies - immunology ; HIV Infections - blood ; HIV Infections - complications ; HIV Infections - epidemiology ; HTLV-I Infections - blood ; HTLV-I Infections - complications ; HTLV-I Infections - epidemiology ; HTLV‐I (human T‐lymphotrophic virus, type I) ; Human T-lymphotropic virus 1 - genetics ; Human T-lymphotropic virus 1 - immunology ; Humans ; HUS (hemolytic uremic syndrome) ; Male ; Medical sciences ; Middle Aged ; Platelet diseases and coagulopathies ; Polymerase Chain Reaction ; Purpura, Thrombotic Thrombocytopenic - blood ; Purpura, Thrombotic Thrombocytopenic - complications ; Purpura, Thrombotic Thrombocytopenic - epidemiology ; Retroviridae Infections - blood ; Retroviridae Infections - complications ; Retroviridae Infections - epidemiology ; Risk Factors ; Survival Analysis ; Time Factors ; TTP (thrombotic thrombocytopenic purpura)</subject><ispartof>American journal of hematology, 1994-04, Vol.45 (4), p.304-309</ispartof><rights>Copyright © 1994 Wiley‐Liss, Inc., A Wiley Company</rights><rights>1994 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4647-a50f0fe97238aa9b4030f78d95451721095349bd2bac923c5355a16aaa3f37e63</citedby><cites>FETCH-LOGICAL-c4647-a50f0fe97238aa9b4030f78d95451721095349bd2bac923c5355a16aaa3f37e63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fajh.2830450407$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fajh.2830450407$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=3985921$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7909982$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ucar, Antonio</creatorcontrib><creatorcontrib>Fernandez, Hugo F.</creatorcontrib><creatorcontrib>Byrnes, John J.</creatorcontrib><creatorcontrib>Lian, Eric C‐Y</creatorcontrib><creatorcontrib>Harrington, William J.</creatorcontrib><title>Thrombotic microangiopathy and retroviral infections: A 13‐year experience</title><title>American journal of hematology</title><addtitle>Am J Hematol</addtitle><description>Eleven of fifty serum samples collected from patients with a diagnosis of thrombotic microangiopathy (TMA), from 1979 to 1991, tested positive for antlretroviral antibodies. Seven had human immunodeficiency virus (HIV) infection, and four had human iymphotrophic virus, type I (HTLV‐I) infection. All patients were treated with plasma exchange and for infusion, but only two of the HIV‐infected patlents obtained a complete response (CR) and one of them died after a few months. Combined results from the ilterature indicate that most patients with HIV infection survive less than one year from the initial diagnosis of TMA. In the setting of HIV infection, TMA Is a treatable condition, but survivai for most patients is less than 12 months. Three of the four HTLV‐I infected patients with TMA had a CR. These observations strongly suggest that both HIV and HTLV‐I infections are associated with TMA, but rigorous epidemiologic studies will be needed to determine the relative risk for each. Retrovirai Infections should be considered In patients with TMA, especially If the patient has associated risk factors and demographic characteristics. © 1994 Wiley‐Liss, Inc.</description><subject>Adult</subject><subject>AIDS (acquired immunodeficiency syndrome)</subject><subject>AIDS-Related Opportunistic Infections - blood</subject><subject>AIDS-Related Opportunistic Infections - epidemiology</subject><subject>AIDS/HIV</subject><subject>Biological and medical sciences</subject><subject>Deltaretrovirus Antibodies - analysis</subject><subject>Deltaretrovirus Antibodies - immunology</subject><subject>DNA, Viral - analysis</subject><subject>DNA, Viral - genetics</subject><subject>Female</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Hemolytic-Uremic Syndrome - blood</subject><subject>Hemolytic-Uremic Syndrome - complications</subject><subject>Hemolytic-Uremic Syndrome - epidemiology</subject><subject>HIV (human immunodeficiency virus)</subject><subject>HIV - genetics</subject><subject>HIV - immunology</subject><subject>HIV Antibodies - analysis</subject><subject>HIV Antibodies - immunology</subject><subject>HIV Infections - blood</subject><subject>HIV Infections - complications</subject><subject>HIV Infections - epidemiology</subject><subject>HTLV-I Infections - blood</subject><subject>HTLV-I Infections - complications</subject><subject>HTLV-I Infections - epidemiology</subject><subject>HTLV‐I (human T‐lymphotrophic virus, type I)</subject><subject>Human T-lymphotropic virus 1 - genetics</subject><subject>Human T-lymphotropic virus 1 - immunology</subject><subject>Humans</subject><subject>HUS (hemolytic uremic syndrome)</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Platelet diseases and coagulopathies</subject><subject>Polymerase Chain Reaction</subject><subject>Purpura, Thrombotic Thrombocytopenic - blood</subject><subject>Purpura, Thrombotic Thrombocytopenic - complications</subject><subject>Purpura, Thrombotic Thrombocytopenic - epidemiology</subject><subject>Retroviridae Infections - blood</subject><subject>Retroviridae Infections - complications</subject><subject>Retroviridae Infections - epidemiology</subject><subject>Risk Factors</subject><subject>Survival Analysis</subject><subject>Time Factors</subject><subject>TTP (thrombotic thrombocytopenic purpura)</subject><issn>0361-8609</issn><issn>1096-8652</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1994</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkLlOw0AQQFcIFEKgpUNygegSZi_bSxdFQECRaEJtjddrspGPsOsA6fgEvpEvwVGsQEc1I82b6xFyTmFEAdg1LhcjFnMQEgREB6RPQYXDOJTskPSBh7TNQR2TE--XAJSKGHqkFylQKmZ9MpsvXF2mdWN1UFrtaqxebL3CZrEJsMoCZxpXv1mHRWCr3OjG1pW_CcYB5d-fXxuDLjAfK-OsqbQ5JUc5Ft6cdXFAnu9u55PpcPZ0_zAZz4ZahCIaooQccqMixmNElQrgkEdxpqSQNGLtA5ILlWYsRa0Y15JLiTRERJ7zyIR8QK52c1eufl0b3ySl9doUBVamXvskCkXcKtmCox3YPua9M3mycrZEt0koJFt9Sasv-dXXNlx0k9dpabI93vlq65ddHb3GIndYaev3GFexVIy2mNph77Ywm3-WJuPH6Z8TfgBg44ii</recordid><startdate>199404</startdate><enddate>199404</enddate><creator>Ucar, Antonio</creator><creator>Fernandez, Hugo F.</creator><creator>Byrnes, John J.</creator><creator>Lian, Eric C‐Y</creator><creator>Harrington, William J.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199404</creationdate><title>Thrombotic microangiopathy and retroviral infections: A 13‐year experience</title><author>Ucar, Antonio ; Fernandez, Hugo F. ; Byrnes, John J. ; Lian, Eric C‐Y ; Harrington, William J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4647-a50f0fe97238aa9b4030f78d95451721095349bd2bac923c5355a16aaa3f37e63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1994</creationdate><topic>Adult</topic><topic>AIDS (acquired immunodeficiency syndrome)</topic><topic>AIDS-Related Opportunistic Infections - blood</topic><topic>AIDS-Related Opportunistic Infections - epidemiology</topic><topic>AIDS/HIV</topic><topic>Biological and medical sciences</topic><topic>Deltaretrovirus Antibodies - analysis</topic><topic>Deltaretrovirus Antibodies - immunology</topic><topic>DNA, Viral - analysis</topic><topic>DNA, Viral - genetics</topic><topic>Female</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Hemolytic-Uremic Syndrome - blood</topic><topic>Hemolytic-Uremic Syndrome - complications</topic><topic>Hemolytic-Uremic Syndrome - epidemiology</topic><topic>HIV (human immunodeficiency virus)</topic><topic>HIV - genetics</topic><topic>HIV - immunology</topic><topic>HIV Antibodies - analysis</topic><topic>HIV Antibodies - immunology</topic><topic>HIV Infections - blood</topic><topic>HIV Infections - complications</topic><topic>HIV Infections - epidemiology</topic><topic>HTLV-I Infections - blood</topic><topic>HTLV-I Infections - complications</topic><topic>HTLV-I Infections - epidemiology</topic><topic>HTLV‐I (human T‐lymphotrophic virus, type I)</topic><topic>Human T-lymphotropic virus 1 - genetics</topic><topic>Human T-lymphotropic virus 1 - immunology</topic><topic>Humans</topic><topic>HUS (hemolytic uremic syndrome)</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Platelet diseases and coagulopathies</topic><topic>Polymerase Chain Reaction</topic><topic>Purpura, Thrombotic Thrombocytopenic - blood</topic><topic>Purpura, Thrombotic Thrombocytopenic - complications</topic><topic>Purpura, Thrombotic Thrombocytopenic - epidemiology</topic><topic>Retroviridae Infections - blood</topic><topic>Retroviridae Infections - complications</topic><topic>Retroviridae Infections - epidemiology</topic><topic>Risk Factors</topic><topic>Survival Analysis</topic><topic>Time Factors</topic><topic>TTP (thrombotic thrombocytopenic purpura)</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ucar, Antonio</creatorcontrib><creatorcontrib>Fernandez, Hugo F.</creatorcontrib><creatorcontrib>Byrnes, John J.</creatorcontrib><creatorcontrib>Lian, Eric C‐Y</creatorcontrib><creatorcontrib>Harrington, William J.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ucar, Antonio</au><au>Fernandez, Hugo F.</au><au>Byrnes, John J.</au><au>Lian, Eric C‐Y</au><au>Harrington, William J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Thrombotic microangiopathy and retroviral infections: A 13‐year experience</atitle><jtitle>American journal of hematology</jtitle><addtitle>Am J Hematol</addtitle><date>1994-04</date><risdate>1994</risdate><volume>45</volume><issue>4</issue><spage>304</spage><epage>309</epage><pages>304-309</pages><issn>0361-8609</issn><eissn>1096-8652</eissn><coden>AJHEDD</coden><abstract>Eleven of fifty serum samples collected from patients with a diagnosis of thrombotic microangiopathy (TMA), from 1979 to 1991, tested positive for antlretroviral antibodies. Seven had human immunodeficiency virus (HIV) infection, and four had human iymphotrophic virus, type I (HTLV‐I) infection. All patients were treated with plasma exchange and for infusion, but only two of the HIV‐infected patlents obtained a complete response (CR) and one of them died after a few months. Combined results from the ilterature indicate that most patients with HIV infection survive less than one year from the initial diagnosis of TMA. In the setting of HIV infection, TMA Is a treatable condition, but survivai for most patients is less than 12 months. Three of the four HTLV‐I infected patients with TMA had a CR. These observations strongly suggest that both HIV and HTLV‐I infections are associated with TMA, but rigorous epidemiologic studies will be needed to determine the relative risk for each. Retrovirai Infections should be considered In patients with TMA, especially If the patient has associated risk factors and demographic characteristics. © 1994 Wiley‐Liss, Inc.</abstract><cop>New York</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>7909982</pmid><doi>10.1002/ajh.2830450407</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0361-8609
ispartof American journal of hematology, 1994-04, Vol.45 (4), p.304-309
issn 0361-8609
1096-8652
language eng
recordid cdi_proquest_miscellaneous_76488306
source MEDLINE; Wiley Online Library Journals Frontfile Complete
subjects Adult
AIDS (acquired immunodeficiency syndrome)
AIDS-Related Opportunistic Infections - blood
AIDS-Related Opportunistic Infections - epidemiology
AIDS/HIV
Biological and medical sciences
Deltaretrovirus Antibodies - analysis
Deltaretrovirus Antibodies - immunology
DNA, Viral - analysis
DNA, Viral - genetics
Female
Hematologic and hematopoietic diseases
Hemolytic-Uremic Syndrome - blood
Hemolytic-Uremic Syndrome - complications
Hemolytic-Uremic Syndrome - epidemiology
HIV (human immunodeficiency virus)
HIV - genetics
HIV - immunology
HIV Antibodies - analysis
HIV Antibodies - immunology
HIV Infections - blood
HIV Infections - complications
HIV Infections - epidemiology
HTLV-I Infections - blood
HTLV-I Infections - complications
HTLV-I Infections - epidemiology
HTLV‐I (human T‐lymphotrophic virus, type I)
Human T-lymphotropic virus 1 - genetics
Human T-lymphotropic virus 1 - immunology
Humans
HUS (hemolytic uremic syndrome)
Male
Medical sciences
Middle Aged
Platelet diseases and coagulopathies
Polymerase Chain Reaction
Purpura, Thrombotic Thrombocytopenic - blood
Purpura, Thrombotic Thrombocytopenic - complications
Purpura, Thrombotic Thrombocytopenic - epidemiology
Retroviridae Infections - blood
Retroviridae Infections - complications
Retroviridae Infections - epidemiology
Risk Factors
Survival Analysis
Time Factors
TTP (thrombotic thrombocytopenic purpura)
title Thrombotic microangiopathy and retroviral infections: A 13‐year experience
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T16%3A28%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Thrombotic%20microangiopathy%20and%20retroviral%20infections:%20A%2013%E2%80%90year%20experience&rft.jtitle=American%20journal%20of%20hematology&rft.au=Ucar,%20Antonio&rft.date=1994-04&rft.volume=45&rft.issue=4&rft.spage=304&rft.epage=309&rft.pages=304-309&rft.issn=0361-8609&rft.eissn=1096-8652&rft.coden=AJHEDD&rft_id=info:doi/10.1002/ajh.2830450407&rft_dat=%3Cproquest_cross%3E76488306%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=76488306&rft_id=info:pmid/7909982&rfr_iscdi=true